Lebwohl, M. G.; Sugarman, J. L.; Gold, L. S.; Lin, T.; Martin, G. Efficacy, Safety, and Tolerability of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination in the Treatment of Severe Plaque Psoriasis: Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials. J of Skin 2019, 3, S29.